Site logo

Novel therapy can improve the prognosis of relapsed/refractory acute myeloid leukemia

Relapsed/refractory acute myeloid leukemia (AML), a so-called blood cancer, has an extremely poor prognosis because of resistance to anti-cancer drugs and frailty of the patient’s organ functions.

Share the Post:

Related Posts

We use cookies to improve your experience on our website. By browsing this website, you agree to our use of cookies.

Sign in

Sign Up

Forgot Password

Cart

Your cart is currently empty.